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During 2016, 6% of persons in the United States who 
received a diagnosis of human immunodeficiency virus (HIV) 
infection had their HIV infection attributed to injection drug 
use (1). Injection practices and sexual behaviors among HIV-
positive persons who inject drugs, such as injection equipment 
sharing and condomless sex, can increase HIV transmission 
risk; nationally representative estimates of the prevalences of 
these behaviors are lacking. The Medical Monitoring Project 
(MMP) is an annual, cross-sectional survey that reports 
nationally representative estimates of clinical and behavioral 
characteristics among U.S. adults with diagnosed HIV (2). 
CDC used MMP data to assess high-risk injection practices 
and sexual behaviors among HIV-positive persons who injected 
drugs during the preceding 12 months and compared their 
HIV transmission risk behaviors with those of HIV-positive 
persons who did not inject drugs. During 2015–2017, approxi-
mately 10% (weighted percentage estimate) of HIV-positive 
persons who injected drugs engaged in distributive injection 
equipment sharing (giving used equipment to another person 
for use); nonsterile syringe acquisition and unsafe disposal 
methods were common. Overall, among HIV-positive persons 
who injected drugs, 80% received no treatment, and 57% self-
reported needing drug or alcohol treatment. Compared with 
HIV-positive persons who did not inject drugs, those who 
injected drugs were more likely to have a detectable viral load 
(48% versus 35%; p = 0.008) and engage in high-risk sexual 
behaviors (p<0.001). Focusing on interventions that reduce 
high-risk injection practices and sexual behaviors and increase 
rates of viral suppression might decrease HIV transmission 
risk among HIV-positive persons who inject drugs. Successful 
substance use treatment could also lower risk for transmission 
and overdose through reduced injection.
MMP uses a two-stage sampling method. In the first stage, 
23 jurisdictions are sampled from all U.S. states, the District of 
Columbia, and Puerto Rico. Next, simple random samples of 
adults with diagnosed HIV infection from sampled jurisdictions 
are selected from the National HIV Surveillance System, a census 
of persons with diagnosed HIV infection (1). During June 2015–
May 2017, face-to-face or telephone interviews were conducted 
with participants, during which demographic characteristics, 
injection practices and sexual behaviors, and need for, and receipt 
of, medical services were assessed for the preceding 12 months. 
Response rates for 2 cycle years of data were 100% (jurisdictions) 
and 40%–44% (adults with diagnosed HIV infection).
Among HIV-positive persons who injected drugs, behav-
iors during the preceding 12 months were self-reported. 
Injection practices included distributive sharing of syringes 
and other injection equipment,* injection before or during 
* Includes frontloading/backloading into a syringe, a process in which one syringe 
is used to prepare a drug solution that is then divided into one or more syringes 
for injection.
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sex, and methods for injection syringe acquisition and disposal. 
Participants self-reported need for, and receipt of, alcohol or 
drug treatment. Persons who reported receiving, or not receiv-
ing but needing, drug or alcohol treatment were considered to 
have a need for this service. Enrollment in a medication-assisted 
treatment program for opioid use disorder was also assessed. 
Sexual behaviors were assessed, including 1) condomless sex; 
2) exchange of sex for money or goods; and 3) a dichotomous 
measure indicative of high risk for sexual HIV transmission 
(defined as having one or more detectable viral loads in the past 
12 months and having high-risk sex). High-risk sex was defined 
as condomless sex with an HIV-negative partner or a partner 
whose HIV status was unknown and who was not known to 
be on preexposure prophylaxis (PrEP).† Viral loads from the 
preceding 12 months were abstracted from medical records.
Weighted percentages of characteristics with correspond-
ing 95% confidence intervals (CIs) were reported to account 
for complex survey design using standard methodology (2). 
Rao-Scott chi-square tests were used to compare characteris-
tics associated with a high risk for sexual HIV transmission 
between HIV-positive persons who injected drugs (233) and 
those who did not inject drugs (7,397); p< 0.05 indicated 
statistical significance. All analyses were conducted using SAS 
(version 9.4; SAS Institute).
An estimated 3% (95% CI = 2%–3%) of persons with 
diagnosed HIV infection injected drugs in the preceding 
† https://www.cdc.gov/hiv/risk/prep/index.html.
12 months. Among HIV-positive persons who injected drugs, 
11% engaged in distributive sharing of syringes, and 10% 
engaged in distributive sharing of other injection equipment; 
61% injected before or during sex (Table). Common sources 
of injection syringes included a pharmacy or drug store (63%); 
a friend, relative, or sex partner (50%); a syringe services 
program (SSP) (32%); or a needle or drug dealer, shooting 
gallery, or off the street (21%). Common methods for syringe 
disposal were in the trash, on the street, or in a nonmedical 
waste container (53%); a medical waste container (50%); 
an SSP (30%); or keeping the syringe to reuse it (29%). An 
estimated 57% percent of HIV-positive persons who injected 
drugs reported needing alcohol or drug use treatment; 80% 
of HIV-positive persons who injected drugs did not obtain 
treatment in the preceding year. Eight percent of HIV-positive 
persons who injected drugs enrolled in a medication-assisted 
treatment program.
A higher percentage of HIV-positive persons who injected 
drugs had a detectable viral load than did those who did not 
inject drugs (48% versus 35%; p = 0.008) (Figure). Condomless 
sex, exchange sex, and high-risk sex were all more prevalent 
among HIV-positive persons who injected drugs (63%, 17%, 
and 18%, respectively), than among those who did not inject 
drugs (31%, 2%, and 6%, respectively) (p<0.001).
Discussion
Substantial high-risk injection practices and sexual behav-
iors associated with HIV transmission were observed among 
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HIV-positive persons who injected drugs. Nonsterile syringe 
acquisition and unsafe disposal methods were common and 
demonstrate the need for additional outreach for harm reduc-
tion. Although a considerable need for drug and alcohol 
treatment was reported, 80% of HIV-positive persons who 
injected drugs did not obtain services, which highlights the 
need to expand access and referral to treatment services to 
reach these persons.
These findings underscore the importance of implementing a 
multipronged intervention approach to reducing HIV transmis-
sion among HIV-positive persons who inject drugs, including 
expanding access to sterile injection equipment and education 
regarding harm reduction and condom use (3). Improving access 
to substance use treatment might decrease HIV transmission 
risk through reduced need for injection. Medication-assisted 
treatment is one evidence-based option for opioid use disorder 
treatment (4). Viral suppression is essential for reducing HIV 
transmission risk and improving long-term outcomes among 
persons with diagnosed HIV infection (5). Continuing to 
improve retention in care and adherence to antiretroviral therapy 
among HIV-positive persons who inject drugs could increase the 
prevalence of viral suppression in this population.
Colocating HIV prevention services, such as provision of 
PrEP, condoms, sterile injection equipment, and HIV medical 
care, might also reduce the burden for patients by addressing 
complex public health issues in a single setting (3). SSPs are an 
important HIV prevention strategy among persons who inject 
drugs and could be a setting for provision of these services 
(6). Recent guidance from the U.S. Department of Health 
and Human Services specifies allowance of federal funds to 
support SSPs when there is a documented need and when 
the SSPs are in compliance with local laws.§ However, many 
states require legislative action to permit implementation and 
operation of SSPs.¶
A large proportion of HIV-positive persons who injected 
drugs received syringes from sources that provided sterile 
equipment, such as an SSP or a pharmacy or drug store; how-
ever, potentially nonsterile sources were also commonly used. 
Receipt and use of nonsterile syringes can increase the risk 
for acquisition of hepatitis C virus (HCV) infection among 
persons with HIV infection; co-infection with HCV can result 
in poorer clinical outcomes (7).**
In addition, a large proportion of HIV-positive persons who 
injected drugs disposed of syringes unsafely, increasing the risk 
of needle-stick injuries and transmission of HIV and HCV to 
others (8). Instead of disposing of syringes after first use, nearly 
30% kept syringes to reuse them, which increases the risk for 
serious bacterial infections, including endocarditis and skin 
abscesses (9). Improving access to sterile injection equipment and 
harm reduction education might help to decrease the occurrence 
of these infections, as well as the transmission of HIV and viral 
hepatitis through injection equipment sharing (6).
The findings in this report are subject to at least three limi-
tations. First, all characteristics ascertained through interview 
are based on self-report and might be subject to information 
bias. Second, not all sampled persons participated in MMP, but 
results were adjusted for nonresponse using standard method-
ology. Even with suboptimal response rates, results obtained 
using unbiased sampling methodology have value.†† Finally, 
 § https://www.hiv.gov/sites/default/files/hhs-ssp-guidance.pdf.
 ¶ https://www.nastad.org/maps/syringe-service-program-policy-environments-
across-united-states.
 ** https://www.cdc.gov/hepatitis/hcv/cfaq.htm.
 †† https://www.sciencedirect.com/science/article/pii/S2352146515002987.
TABLE. Injection behaviors and substance use treatment in the 
preceding 12 months among persons with diagnosed human 
immunodeficiency virus (HIV) who injected drugs (n = 233) — 
Medical Monitoring Project, 2015–2017 
Behavior/Treatment
HIV-positive 
persons who 
injected drugs
No.
Weighted % 
(95% CI)
Distributive sharing of syringes*
Yes 22 11 (6–17)
No 204 89 (83–94)
Distributive sharing of other nonsyringe injection equipment
Yes 28 10 (6–14)
No 198 90 (86–94)
Injection before or during sex
Yes 141 61 (53–69)
No 87 39 (31–47)
Reported sources of syringes†
Syringe services program 89 32 (20–44)
Pharmacy/Drug store 136 63 (54–72)
Doctor’s office/Clinic/Hospital 15 5 (3–8)
Friend, relative, sex partner 111 50 (42–58)
Needle or drug dealer, shooting gallery, or off the street 50 21 (15–26)
Disposal of syringes†
Trash/Street/Container not for medical waste 119 53 (43–63)
Kept it to reuse it 58 29 (22–35)
Put in a medical waste container 126 50 (39–61)
Took it to a syringe services program 76 30 (19–41)
Need for drug or alcohol treatment§
Yes 134 57 (50–64)
No 99 43 (36–50)
Obtained drug or alcohol treatment
Yes 40 20 (13–26)
No 193 80 (74–87)
Enrolled in medication-assisted treatment program
Yes 25 8 (4–12)
No 208 92 (88–96)
* Defined as giving used injection equipment to another person for use.
† Participants could report more than one response; thus, categories are not 
mutually exclusive and percentages might sum to >100%.
§ Yes responses included all persons who self-reported a need for treatment, 
whether or not they received it.
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FIGURE. Percentage of persons with diagnosed human immunodeficiency virus (HIV) (n = 233) who engaged in high risk sexual behaviors or 
had a detectable viral load — Medical Monitoring Project, United States, 2015–2017*,†  
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* With 95% confidence intervals indicated with error bars; all percentages are weighted.
† Exchange sex was defined as exchanging sex for money or goods in the preceding 12 months; high-risk sex was defined as having one or more detectable viral 
loads in the preceding 12 months and having condomless sex with an HIV-negative or HIV-unknown partner who was not known to be on preexposure prophylaxis.
the sample size of HIV-positive persons who injected drugs 
was limited; as additional data are collected in future MMP 
cycles, reliability of estimates should improve.
Focusing HIV prevention strategies on both high-risk sexual 
behaviors and injection practices among HIV-positive persons 
who inject drugs might reduce HIV transmission risk. Through 
collaborations with state and local health departments, CDC 
supports projects to prioritize HIV prevention strategies for 
persons who inject drugs. One such project, Community 
PROMISE,§§ uses peer advocates to reach persons who inject 
drugs and communicate public health messages around risk 
reduction. CDC has also expanded efforts to work with state 
and local health departments to detect clusters of HIV infection 
among important populations, including persons who inject 
drugs, and provides support in local investigations of these clus-
ters.¶¶ CDC recommends that all persons with diagnosed HIV 
infection receive partner services, which includes interviews 
regarding sexual behaviors and injection practices, education 
about harm reduction interventions, and identification of 
 §§ https://effectiveinterventions.cdc.gov/Files/promiseoverview.pdf.
 ¶¶ https://www.cdc.gov/hiv/funding/announcements/ps18-1802/index.html.
sexual and injection equipment-sharing contacts, so that HIV 
and sexually transmitted disease testing can be offered (10).*** 
Ensuring safe methods for acquisition and disposal of syringes 
could decrease risks of acquiring bloodborne pathogens. CDC 
supports the use of SSPs as part of a comprehensive HIV 
prevention strategy and provides guidance on support of SSP 
activities (10). Continued efforts to reduce sexual and injection 
HIV transmission risk through support for expanding access 
to sterile injection equipment, drug treatment services, PrEP, 
and education around harm reduction and condom use might 
strengthen HIV prevention programs and directly support the 
national initiative to end the HIV epidemic.†††
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Summary
What is already known about this topic?
Certain injection and sexual behaviors among human immuno-
deficiency virus (HIV)–positive persons who inject drugs (PWID) 
can increase HIV transmission risk. Successful substance use 
treatment could lower risk of infection and overdose through 
reduced injection.
What is added by this report?
Approximately 10% of HIV-positive PWID engaged in distribu-
tive injection equipment sharing; nonsterile syringe acquisition 
and unsafe disposal methods were common. HIV-positive PWID 
were also more likely to have engaged in high-risk sexual 
behaviors. Eighty percent did not receive treatment for 
substance use.
What are the implications for public health practice?
Increasing access to sterile injection equipment, drug treatment 
services, and education around harm reduction and condom 
use might reduce HIV transmission among sexual and injection 
partners of HIV-positive PWID.
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